The DOI matches its Crossref record; the references it cites are not checked yet.
The CX3CL1/CX3CR1 reprograms glucose metabolism through HIF-1 pathway in pancreatic adenocarcinoma: The CX3CL1/CX3CR1/HIF-1 Pathway Reprogrammes Glucose Metabolism
Abstract
One of the hallmarks of cancer is revised glucose metabolism that promotes cell survival and proliferation. In pancreatic cancer, the regulatory mechanism of glucose metabolism remains to be elucidated. In this study, we found that CX3CR1 is expressed in pancreatic cancer cells lines. Exogenous or transfected CX3CL1 increased glucose uptake and lactate secretion. CX3CL1 stimulated HIF-1 expression through PI3K/Akt and MAPK pathways. Furthermore, knockdown of HIF-1 blocked CX3CL1-modified glucose metabolism in pancreatic adenocarcinoma cells. In conclusion, the CX3CL1/CX3CR1 reprograms glucose metabolism through HIF-1 pathway in pancreatic cancer cells.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
HIF-1α can decrease ROS production by reprogramming glucose metabolism.
“and HIF-1α can decrease ROS production by reprogramming glucose metabolism [37].”
From Inhibition of HIF-1α by PX-478 enhances the anti-tumor effect of gemcitabine by inducing immunogenic cell death in pancreatic ductal adenocarcinoma (2015) · cites this paper as [37]
Citations
The citation lists haven’t been fetched yet
References 26 · Cited by 20
Research works printed but not linked: 24
- Chen, 2003, Dominant-negative hypoxia-inducible factor-1 alpha reduces tumorigenicity of pancreatic cancer cells through the suppression of glucose metabolism, Am J Pathol, 162, 1283, 10.1016/S0002-9440(10)63924-7 · DOI
- Deberardinis, 2008, Brick by brick: Metabolism and tumor cell growth, Curr Opin Genet Dev, 18, 54, 10.1016/j.gde.2008.02.003 · DOI · Paper page
- Dores, 2012, Ubiquitination of G protein-coupled receptors: Functional implications and drug discovery, Mol Pharmacol, 82, 563, 10.1124/mol.112.079418 · DOI
- Farrow, 2002, Inflammation and the development of pancreatic cancer, Surg Oncol, 10, 153, 10.1016/S0960-7404(02)00015-4 · DOI · Paper page
- Gaudin, 2011, Identification of the chemokine CX3CL1 as a new regulator of malignant cell proliferation in epithelial ovarian cancer, PLoS ONE, 6, e21546, 10.1371/journal.pone.0021546 · DOI
- Imai, 1997, Identification and molecular characterization of fractalkine receptor CX3CR1, which mediates both leukocyte migration and adhesion, Cell, 91, 521, 10.1016/S0092-8674(00)80438-9 · DOI
- Koppenol, 2011, Otto Warburg's contributions to current concepts of cancer metabolism, Nat Rev Cancer, 11, 325, 10.1038/nrc3038 · DOI · Paper page
- Koukourakis, 2006, Comparison of metabolic pathways between cancer cells and stromal cells in colorectal carcinomas: A metabolic survival role for tumor-associated stroma, Cancer Res, 66, 632, 10.1158/0008-5472.CAN-05-3260 · DOI
- Liao, 2007, Hypoxia: A key regulator of angiogenesis in cancer, Cancer Metastasis Rev, 26, 281, 10.1007/s10555-007-9066-y · DOI
- Marchese, 2001, Agonist-promoted ubiquitination of the G protein-coupled receptor CXCR4 mediates lysosomal sorting, J Biol Chem, 7, 45509, 10.1074/jbc.C100527200 · DOI
- Marchesi, 2008, The chemokine receptor CX3CR1 is involved in the neural tropism and malignant behavior of pancreatic ductal adenocarcinoma, Cancer Res, 68, 9060, 10.1158/0008-5472.CAN-08-1810 · DOI
- Ransohoff, 2009, Chemokines and chemokine receptors: Standing at the crossroads of immunobiology and neurobiology, Immunity, 31, 711, 10.1016/j.immuni.2009.09.010 · DOI
- Rodriguez-Enriquez, 2009, Targeting of cancer energy metabolism, Mol Nutr Food Res, 53, 29, 10.1002/mnfr.200700470 · DOI
- Ryu, 2008, Activation of fractalkine/CX3CR1 by vascular endothelial cells induces angiogenesis through VEGF-A/KDR and reverses hindlimb ischaemia, Cardiovasc Res, 78, 333, 10.1093/cvr/cvm067 · DOI
- Semenza, 2011, Regulation of metabolism by hypoxia-inducible factor 1, Cold Spring Harb Symp Quant Biol, 76, 347, 10.1101/sqb.2011.76.010678 · DOI · Paper page
- Shulby, 2004, CX3CR1-fractalkine expression regulates cellular mechanisms involved in adhesion, migration, and survival of human prostate cancer cells, Cancer Res, 64, 4693, 10.1158/0008-5472.CAN-03-3437 · DOI
- Sun, 2010, CXCL12/CXCR4/CXCR7 chemokine axis and cancer progression, Cancer Metastasis Rev, 29, 709, 10.1007/s10555-010-9256-x · DOI
- Tanimoto, 2010, Role of glucose metabolism and cellularity for tumor malignancy evaluation using FDG-PET/CT and MRI, Nucl Med Commun, 31, 604, 10.1097/MNM.0b013e328339350c · DOI
- Tsao, 2000, Down-regulation of G protein-coupled receptors, Curr Opin Neurobiol, 10, 365, 10.1016/S0959-4388(00)00096-9 · DOI
- Vander Heiden, 2009, Understanding the Warburg effect: The metabolic requirements of cell proliferation, Science, 324, 1029, 10.1126/science.1160809 · DOI · Paper page
- Wang, 2011, Polymorphisms in the hypoxia-inducible factor-1alpha gene confer susceptibility to pancreatic cancer, Cancer Biol Ther, 12, 383, 10.4161/cbt.12.5.15982 · DOI
- Warburg, 1956, On the origin of cancer cells, Science, 123, 309, 10.1126/science.123.3191.309 · DOI · Paper page
- White, 2010, Fractalkine has anti-apoptotic and proliferative effects on human vascular smooth muscle cells via epidermal growth factor receptor signalling, Cardiovasc Res, 85, 825, 10.1093/cvr/cvp341 · DOI
- Xu, 2012, High expression of CX3CL1/CX3CR1 axis predicts a poor prognosis of pancreatic ductal adenocarcinoma, J Gastrointest Surg, 16, 1493, 10.1007/s11605-012-1921-7 · DOI
Metadata
- Authors
- Ren, H., Zhao, T., Sun, J., Wang, X., Liu, J., Gao, S., Yu, M., & Hao, J.
- Affiliations
- Tianjin Medical University Cancer Institute and Hospital (CN)
- Corresponding author
- Hao, Jihui
- Venue
- Journal of Cellular Biochemistry
- Publisher
- Wiley
- Published
- 2013-09-13
- Volume
- 114
- Issue
- 11
- Pages
- 2603-2611
- ISSN
- 0730-2312 (ISSN-L)
- OpenAlex
- W1841453023
- Cited by
- 20
- References
- 26
- Citations by year
- 2025: 2 · 2024: 2 · 2023: 1 · 2022: 3 · 2021: 3 · 2020: 3 · 2019: 1 · 2017: 2 · 2015: 2 · 2014: 1
- FWCI
- 0.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Cellular Biochemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
- Health Sciences › Medicine › Oncology › Chemokine receptors and signaling
- Keywords
- fractalkine, CX3CR1, pancreatic ductal adenocarcinoma, glucose metabolism, HIF-1, PI3K/Akt signaling, MAPK signaling, lactate secretion, glucose uptake, cancer metabolism
- MeSH terms
- CX3C Chemokine Receptor 1, Glucose, Humans, Pancreatic Neoplasms, Gene Expression Regulation, Neoplastic, Receptors, Chemokine, Cell Line, Tumor, Hypoxia-Inducible Factor 1, Chemokine CX3CL1, HEK293 Cells
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
